C. P. Neal, D. P. Berry, H. Doucas, M. M. Manson, W. Steward and G. Garcea Pages 371 - 383 ( 13 )
Natural products represent a rich resource for drug discovery and are currently being exploited to target tumour angiogenesis. A vast array of products of natural origin have been shown to have anti-angiogenic potential in preclinical models, including purified endogenous inhibitors, and exogenous compounds derived from varied species of plant, animal and micro-organism. Over a dozen of these agents have now entered clinical trial. This review discusses evidence for the efficacy of this drug class and key issues in the translation of pre-clinical results into the development of efficacious drugs for clinical use.
Angiogenesis, cancer, therapeutics, proliferation, natural, endogenous
Department of Cancer Studiesand Molecular Medicine, 5th floor, Robert Kilpatrick Clinical SciencesBuilding, Leicester Royal Infirmary, Leicester, LE2 7LX, UK.